BioTuesdays

Tag - H.C. Wainwright

OmniAb Logo
Markets

HCW starts OmniAb at buy; PT $11

H.C. Wainwright launched coverage of OmniAb (NASDAQ:OABI) with a “buy” rating and a price target of $11. The stock closed at $3.88 on Feb. 10. At its core, OmniAb is an antibody discovery, optimization, and licensing...

February 13, 2023
Celularity-Logo
Markets

HCW slashes Celularity PT on pipeline priority changes

H.C. Wainwright reduced its price target for Celularity (NASDAQ:CELU) to $2.50 from $15, but reiterated a “buy” rating, after the company unveiled a strategic shift in its pipeline. The stock closed at $1.05 on Jan. 27...

January 30, 2023
Markets

HCW starts Poseida Therapeutics at buy; PT $15

H.C. Wainwright initiated coverage of Poseida Therapeutics (NASDAQ:PSTX) with a “buy” rating and $15 price target. The stock closed at $5.79 on Jan. 2. Poseida is a clinical-stage biopharmaceutical company focused on...

January 4, 2023
Acurx-Pharma-Logo
Markets

HCW starts Acurx Pharma at buy; PT $14

H.C. Wainwright launched coverage of Acurx Pharmaceuticals (NASDAQ:ACXP) with a “buy” rating and $14 price target. The stock closed at $3.83 on Dec. 16. Acurx is a clinical stage biopharmaceutical company focused on...

December 19, 2022
Affimed Logo
Markets

HCW starts Affimed at buy; PT $6

H.C. Wainwright launched coverage of Affimed NV (NASDAQ:AFMD) with a “buy” rating and $6 price target. The stock closed at $2.04 on Dec. 9. Affimed is a clinical-stage biotechnology company focused on developing innate...

December 12, 2022
Enanta Logo
Markets

HCW starts Enanta Pharma at buy; PT $56

H.C. Wainwright initiated coverage of Enanta Pharmaceuticals (NASDAQ:ENTA) with a “buy” rating and $56 price target. The stock closed at $41.78 on Dec. 8. Enanta’s claim to fame is the discovery of glecaprevir...

December 9, 2022
Opthea Logo
Markets

HCW starts Opthea at buy; PT $14

H.C. Wainwright launched coverage of Opthea (NASDAQ:OPT) with a “buy” rating and $14 price target. The stock closed at $4.97 on Dec. 7. Opthea is focused on patients suffering from retinal eye diseases, such as wet age...

December 8, 2022
ImmunoPrecise Logo
Markets

HCW starts ImmunoPrecise Antibodies at buy; PT $9

H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies (NASDAQ:IPA) with a “buy” rating and price target of $9. The stock closed at $4.93 on Dec. 1. ImmunoPrecise is a contract research organization (CRO) that...

December 2, 2022